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Abstract Exosomes are small membrane vesicles derived from intracellular multivescicular bodies (MVBs) that can
undergo constitutive and regulated secretion from cells. Exosomes can also secrete soluble proteins through
metalloprotease-dependent ectodomain shedding. In this study, we sought to determine whether ErbB1 receptors are
present within exosomes isolated from the human keratinocyte cell line, HaCaT, and whether exosome-associated ErbB1
receptors can undergo further proteolytic processing. We show that full-length transmembrane ErbB1 is secreted in HaCaT
exosomes. EGF treatment and calcium flux stimulated the release of phosphorylated ErbB1 in exosomes but only ligand-
stimulated release was blocked by the ErbB1 kinase inhibitor, AG1478, indicating that ligand-dependent ErbB1 receptor
activation can initiate ErbB1 secretion into exosomes. In addition, other immunoreactive but truncated ErbB1 isoforms
were detected in exosomes suggestive of additional proteolytic processing. We demonstrate that cellular and exosomal
ErbB1 receptors can undergo ectodomain shedding to generate soluble N-terminal ectodomains and membrane-
associated C-terminal remnant fragments (CTFs). ErbB1 shedding was activated by calcium flux and the metalloprotease
activator APMA (4-aminophenylmercuric acetate) and was blocked by a metalloprotease inhibitor (GM6001). Soluble
ErbB1 ectodomains shed into conditioned medium retained the ability to bind exogenous ligand. Our results provide new
insights into the proteolysis, trafficking and fate of ErbB1 receptors and suggest that the novel ErbB1 isoforms may have
functions distinct from the plasma membrane receptor. J. Cell. Biochem. 103: 1783–1797, 2008.  2007 Wiley-Liss, Inc.
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ErbB1 is a member of the ErbB receptor
family and plays an important role in develop-
ment, proliferation, migration, differentiation,
apoptosis and in tumorigenesis [Olayioye et al.,
2000; Yarden and Sliwkowski, 2001]. Whilst the
classical signaling role of ErbB receptors as cell
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surface receptor tyrosine kinases (RTKs) is well
established, more recent findings suggest that
ErbBs can undergo a variety of pre- and post-
translational modifications to generate novel
proteins with differing functions [Rio et al.,
2000; Lin et al., 2001; Ni et al., 2001; Anido et al.,
2006]. Upon ligand binding, the ErbB4 receptor
can undergo ectodomain cleavage by the dis-
integrin metalloprotease TACE/ADAM17 to
shed a soluble extracellular domain [Rio et al.,
2000]. Following this cleavage event, the resid-
ual transmembrane ErbB4 remnant becomes
susceptible to regulated intramembrane proc-
essing and generates a cytosolic C-terminal
fragment (CTF) that is kinase active and can
regulate transcription after nuclear transloca-
tion [Ni et al., 2001; Williams et al., 2004; Clark
et al., 2005]. In other situations, alternate
transcripts of ErbB1 and ErbB3 encode soluble
N-terminal ectodomain receptor isoforms that
are constitutively secreted from cells [Ullrich
et al., 1984; Lee and Maihle, 1998; Baron et al.,
2003]. Interestingly, secreted ErbB1 levels are
significantly decreased in patients with epithe-
lial ovarian cancer, raising the possibility that
soluble ErbB1 could play an as yet unrealized
role as a suppressor of ErbB1-dependent tumor
growth [Baron et al., 2003]. In addition, ErbB2
CTFs can be generated via alternate initiation
of translation from downstream initiation
codons that retain kinase activity, have nuclear
localization and are highly tumorigenic [Anido
et al., 2006]. Furthermore, in some cell types,
full-length ErbB receptor proteins can be
trafficked to the nucleus and can also regulate
transcription [Lin et al., 2001; Offterdinger
et al., 2002; Wang et al., 2004; Giri et al., 2005;
Lo and Hung, 2006].
Exosomes are small (30–100 nm diameter)
membrane vesicles that are formed by intra-
luminal budding within the late endosomal
compartment termed multivesicular bodies
(MVBs). Exosomes can be secreted from cells
upon fusion of MVBs with the plasma mem-
brane [Thery et al., 2002; Andre et al., 2002a;
Raiborg et al., 2003]. Exosome secretion was
originally associated with the removal of un-
wanted membrane components but recent data
suggests a functional role of exosomes in vivo,
particularly within the immune system [Keller
et al., 2006; Li et al., 2006; Johnstone, 2006]. The
soluble forms of several proteins including
CD46, tumor necrosis factor receptor 1 (TNFR1)
and fibroblast growth factor-2 (FGF-2) can be
released from cells within exosomes [Taverna
et al., 2003; Hakulinen et al., 2004; Hawari
et al., 2004]. Moreover, recent studies suggest
ADAM-mediated ectodomain shedding of a
variety of transmembrane proteins including
CD46, CD44 and L1 can also occur in exosomes,
thus providing another mechanism by which
soluble forms of these molecules can be gener-
ated and released into the extracellular envi-
ronment [Gutwein et al., 2003, 2005; Nagano
et al., 2004; Stoeck et al., 2006].
In mammalian cells, EGF stimulation and
calcium flux can promote MVB formation and
intraluminal budding. Upon ligand binding,
ErbB1/ligand complexes are trafficked from
the cell surface into MVBs and both proteins
are subsequently degraded or the receptor is
rerouted to the cell surface [de Gassart et al.,
2004; White et al., 2006]. Although the ErbB1
receptor is an established marker of MVBs
[White et al., 2006], the expression and fate of
ErbB1 in exosomes has not been defined. In this
study, we demonstrate that novel ErbB1 iso-
forms are present in exosomes derived from
HaCaT cells. Both calcium flux and EGF treat-
ment increased trafficking of ErbB1 into exo-
somes but only EGF stimulated trafficking was
dependent on ErbB1 receptor kinase activity.
Other novel truncated ErbB1 isoforms and
metalloprotease-dependent ErbB1 ectodomain
shedding stimulated by calcium flux and APMA
could be detected in exosomal and cellular
compartments of HaCaT cells. We suggest that
the generation and secretion of soluble ErbB1
isoforms from cellular and exosomal compart-
ments may provide alternate paradigms for




The spontaneously immortalized human ker-
atinocyte HaCaT cell line has been described
previously [Crusius et al., 1998]. HaCaT cells
were cultivated in DMEM supplemented with
10% fetal bovine serum (FBS), Penicillin/Strep-
tomycin and 10 mM Glutamine at 378C, 5% CO2
and 100% humidity.
Chemicals and Antibodies
The polyclonal rabbit anti-ErbB1 C-terminus,
monoclonal mouse anti-ErbB1 N-terminal ecto-
domain (clone 528) and anti-HSP70 antibodies
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were obtained from Santa Cruz Biotechnology
(CA). The goat anti-ErbB1 ectodomain antibody
was purchased from R&D Systems (MN) and
the mouse anti-phospho Tyrosine1068 ErbB1
antibody was from BIOMOL International (PA).
The antibody to the C-terminus of ADAM10
(serum 71) has been previously described
[Gutwein et al., 2003] and the antibody to the
ectodomain of ADAM17 (mAb 34/4D) was a kind
gift from Dr. Martin Humphries (University of
Manchester, UK). The mouse monoclonal anti-
bodies to annexin-1, LAMP-1 and BIP/GRP78
were purchased from BD Biosciences (NJ).
The mouse anti-moesin (38/87) antibody was a
kind gift from Dr. Reinhardt Schwartz-Albiez
(DKFZ, Heidelberg, Germany). APMA (4-amino-
phenylmercuric acetate) and PMA (phorbol
12-myristate 13-acetate) were obtained from
Sigma (Taufkirchen, Germany). Ionomycin-
calcium salt, the metalloprotease inhibitor GM
6001 and the ErbB1 kinase inhibitor AG1478
were from Calbiochem (Bad Soden, Germany).
Recombinant EGF was purchased from Roche
Applied Sciences (Mannheim, Germany) and
recombinant BTC and the rabbit anti-BTC
polyclonal antibody were from GroPep Limited
(Adelaide, Australia).
Isolation of Membrane Vesicles
From Conditioned Media
Cells were cultivated for 24 h in serum-free
medium for collection of constitutive vesicles or
treated with or without ionomycin (1 mM) or
PMA (50 ng/ml) for 2 h for collection of vesicles
following cell activation. Tissue culture super-
natants were collected and centrifuged for
20 min at 10,000g to remove cellular debris.
Membrane vesicles were collected by centrifu-
gation at 100,000g for 2.5 h at 48C using a
Beckman SW 40 rotor. Vesicles were directly
dissolved in SDS sample buffer or processed
further for gradient centrifugation as described
below.
FACS Analysis
FACS analysis of isolated vesicles was done
after adsorbing of isolated vesicles to 4 mm
(Surfactant-free) aldehyde-sulfate latex beads
(Interfacial Dynamics Corp., Portland, OR) as
described [Stoeck et al., 2006]. The staining of
beads with mAbs and PE-conjugated secondary
antibodies has been described [Stoeck et al.,
2006]. The indication of apoptosis was meas-
ured using the FITC-Annexin-V kit from BD
(BD Bioscience, Heidelberg, Germany). Stained
beads or cells were analyzed with a FACScan
using Cellquest software (Becton & Dickinson,
Heidelberg, Germany).
Homogenization of Cells for Membrane
Vesicle Preparation
HaCaT cells were scraped from the tissue
culture plate surface and taken up in 10 ml PBS.
Cells were then centrifuged at 300g, resus-
pended in a buffer containing 0.25 M sucrose,
Tris-buffered saline (TBS), 1 mM magnesium
acetate and complete protease inhibitor cocktail
(Roche) and homogenized with a stainless steel
ball-bearing homogenizer as described previ-
ously [Gutwein et al., 2003]. In order to separate
cellular vesicle compartments, the homogenate
was loaded onto a sucrose gradient as described
below.
Sucrose Density Gradient Fractionation of
Vesicles From CM or Cell Homogenates
Vesicles from CM or cell homogenates were
loaded onto the top of a step gradient comprising
layers of 2, 1.3, 1.16, 0.8, 0.5, and 0.25 M sucrose
as described [Gutwein et al., 2003, 2005]. The
gradients were centrifuged for 2.5 h at 100,000g
using a Beckman SW40 rotor. Twelve 1 ml
fractions were collected from the top of the
gradient and proteins precipitated with chloro-
form/methanol. Samples were analyzed by
SDS–PAGE and Western blotting.
Cell Surface Biotinylation
Cell surface proteins were biotinylated using
EZ-Link Sulfo-NHS-Biotin-Reagent (Pierce).
After washing cells for 2 times with icecold
PBS, cell surface proteins were labeled by
incubation with 0.5 mg/ml biotin reagent for
30 min at 48C. The reaction was stopped by
washing the cells with 100 mM glycine/PBS.
Isolation of Shed ErbB1 Ectodomains From CM
For constitutive shedding of ErbB1, HaCaT
cells were cultured for 24 h in serum-free
medium. For activated shedding, cells were
treated for 2 h using ionomycin (1 mM), APMA
(50 mM) or PMA (50 ng/ml). CM was collected
and cellular debris and membrane vesicles
removed by centrifugation at 10,000g for
20 min and 100,000g for 2.5 h, respectively.
The cleared supernatant was then incubated
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overnight at 48C with 2 mg of the mouse anti-
ErbB1 ectodomain antibody in the presence of
complete protease inhibitor cocktail (Roche).
Protein A-Sepharose (GE Healthcare, Freiburg,
Germany) was then added and the mixture
further incubated for 4 h at 48C. Immunopreci-
pitates were isolated by centrifugation at
10,000g and washed twice with ice-cold PBS.
Proteins were solubilized by direct addition of
SDS–PAGE sample buffer in preparation for
Western blot.
Biochemical Analysis
SDS–PAGE under reducing conditions and
transfer of proteins to Immobilon membranes
(Millipore) using semi-dry blotting has been
described previously [Gutwein et al., 2000,
2003]. After blocking with 5% non-fat milk in
TBS, blots were developed with the respective
primary antibody followed by peroxidase con-
jugated secondary antibody and ECL detection.
Confocal Immunohistochemistry
and Electron Microscopy
The staining of cells grown on glass cover slips
with primary antibodies and Cy3-conjugated
secondary antibodies has been described pre-
viously [Mechtersheimer et al., 2001]. Vesicles
from HaCaT cells cultured under constitutive
conditions for 24 h in serum-free DMEM were
collected and analyzed using a Zeiss 10 Å
electron microscope as previously described
[Gutwein et al., 2003].
Binding of ErbB1 Ectodomains to Betacellulin
To analyze the ability of shed ErbB1 ectodo-
mains to bind EGF-like factors, the ErbB1
ectodomains were first concentrated. One hun-
dred fifty milliliters of CM from ten 150 mm
plates of confluent HaCaT cells treated with
ionomycin was first cleared of exosomes and
other membranes by ultracentrifugation as
described above. The cleared CM was then
concentrated to 2 ml using centrifugal filter
devices (Millipore, 100 kDa cut-off). Recombi-
nant betacellulin (BTC) was then mixed over-
night at 48C with 500 ml of concentrated CM in
the presence of complete protease inhibitor
cocktail and 0.01% sodium azide. Immunopre-
cipitation was then performed with the mouse
monoclonal anti-ErbB1 ectodomain antibody as
described above. Following washing four times
with ice-cold PBS, immunoprecipitates were
solubilized in SDS–PAGE sample buffer and
analyzed by Western blot using the rabbit
anti-BTC polyclonal and goat anti-ErbB1 ecto-
domain antibodies.
RESULTS
The ErbB1 Receptor is Secreted
From HaCaT Cells in Exosomes
Previous studies have demonstrated that
internalized ErbB1 receptors accumulate within
MVBs and associated intra luminal vesicles
(ILVs) prior to degradation in lysosomes [Futter
et al., 1993, 1996; de Gassart et al., 2004; White
et al., 2006]. To investigate whether ErbB1
receptors could also be released within exo-
somes from cells, we examined constitutive and
regulated exosomal release from human kera-
tinocyte HaCaT cells, which express endoge-
nous ErbB1 receptors. Treatment of HaCaT
cells with ionomycin, but not phorbol esters, led
to a decrease in total cellular levels of ErbB1
(Fig. 1A). Two ErbB1 isoforms were identified of
approximately 185 and 120 kDa that correspond
to the major full-length glycosylated and minor
full-length non-glycosylated proteins, respec-
tively [Gamou and Shimizu, 1988].
To determine whether the loss of cellular
ErbB1 upon ionomycin treatment was due to
release of membrane- and/or vesicle-associated
ErbB1 from cells, conditioned media (CM) from
HaCaT cells was ultracentrifuged and pelleted
membranes were examined for ErbB1 expres-
sion. An antibody to the C-terminus of ErbB1
readily detected the full-length 185 kDa ErbB1
receptor in the membrane pellet of ionomycin
treated cells (Fig. 1B). Moreover, smaller ErbB1
fragments were detected implying that ErbB1
may undergo proteolytic processing. In addi-
tion, the full-length ErbB1 and an additional
55 kDa ErbB1 C-terminal fragment were phos-
phorylated at the autophosphorylation site
tyrosine1068 [Hunter and Cooper, 1985].
Exosomes are released from cells by fusion of
MVBs with the plasma membrane and express
specific marker proteins including moesin,
annexin-1, heat shock protein 70 (HSP70) and
the metalloproteases ADAM10 and ADAM17
[Stoeck et al., 2006]. To determine whether the
ErbB1 proteins were present in exosomes, the
vesicle pellet from ionomycin-treated HaCaT
cells was resuspended and submitted to sucrose
density fractionation followed by analysis of
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expression of exosomal markers. Western blot
analysis of fractionated sucrose density gra-
dients showed that the majority of immunor-
eactive ErbB1 and phospho-ErbB1 was detected
within the exosomal fractions 3–6 of the
gradient confirming that ErbB1 was indeed
released from cells within exosomes (Fig. 1C).
ErbB1-containing exosomes could also be iso-
lated from CM of cells cultured for 24 h in
serum-free DMEM with a density of 1.06–
1.11 g/ml implying that constitutive secretion
of ErbB1 in exosomes can occur under physio-
logical conditions in vivo. Vesicles from HaCaT
cells were also analyzed by electron microscopy
(EM). Consistent with previous reports [Andre
et al., 2002b; Gill et al., 2005], vesicles from
HaCaT cells showed a typical disk-like exoso-
mal structure with a diameter of between
approximately 30 and 100 nm (Fig. 1D).
Exosomal transmembrane proteins have an
orientation identical to that of cell surface
proteins. To determine the orientation of ErbB1
on within exosomes, we immobilized HaCaT
derived exosomes onto latex beads and carried
out FACS analysis. Vesicles were readily
stained with an antibody against the ecto-
domain of ErbB1, supporting the notion that
HaCaT exosomes contain ErbB1 and that the
receptor has the same orientation as its cell
surface counterpart (Fig. 1E).
ErbB1 Within Exosomes Is Derived
From an Intracellular Vesicle Pool
Exosomes are formed by invagination and
budding from the limiting membrane of late
endosomes and accumulate within MVBs from
where they are released by fusion with the
plasma membrane [Raiborg et al., 2003]. To
investigate the cellular origin of exosomes
detected in CM, a sucrose gradient fractionation
procedure was used to separate distinct sub-
cellular membrane compartments within un-
treated HaCaT cell homogenates [Stoeck et al.,
2006]. ErbB1 localized at the plasma membrane
and within the intracellular vesicle/Golgi/Trans
Golgi Network (TGN) fractions of the gradient
(Fig. 2A). These ErbB1-positive intracellular
vesicles had the same buoyant density as
ErbB1-positive secreted exosomes (see Figs. 1C
and 2A) and had a similar profile of ErbB1
Fig. 1. Identification of soluble ErbB1 associated with secreted
membrane vesicles. A: Equal numbers of HaCaT cells were
treated for 2 h in serum-free medium with or without ionomycin
(1 mM) or PMA (50 ng/ml). Cell lysates were collected by direct
lysis in SDSPAGE sample buffer and then analyzed by Western
blot using antibodies against the ErbB1 C-terminus and ß-Actin.
B: Conditioned media (CM) from HaCaT cells treated with
ionomycin or PMA, as above, were collected and membrane
vesicles isolated by ultracentrifugation. Vesicles were directly
taken up in SDS–PAGE sample buffer and analyzed by Western
blot using antibodies against the ErbB1 C-terminus and phospho
ErbB1 C-terminus (residue Tyr1068). C: Vesicles from HaCaT CM
were isolated as in (B). The vesicle pellet is a mixture of exosome
and membrane bleb components [Stoeck et al., 2006]. To
separate these components, vesicles were centrifuged on a
sucrose step gradient as described in the experimental
procedures section. Protein fractions from the gradient were
analyzed by Western blotting using the anti-ErbB1 C-terminus
antibody and a range of other exosomal marker proteins and
disintegrin metalloproteases as indicated. The density of each
fraction of the gradient is shown. D: Vesicles from HaCaT cells
were collected by ultracentrifugation and then resuspended in
PBS in preparation for electron microscopy at 48,000
magnification. Exosomes displayed a disk like structure consis-
tent with the findings of other groups [Andre et al., 2002b; Gill
et al., 2005]. E: Isolated vesicles were adsorbed to latex beads
and subjected to FACS analysis using an antibody to the
ectodomain of ErbB1.
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immunoreactive fragments as secreted exo-
somes (Fig. 2B and refer also to Fig. 1B),
whereas the plasma membrane/endoplasmic
reticulum fractions only contained the intact,
full-length glycosylated (185 kDa) and non-
glycosylated (120 kDa) ErbB1 receptor isoforms
(Fig. 2B). This data is consistent with the
ErbB1-immunoreactive intracellular vesicles
being functionally and biochemically related to
the ErbB-immunoreactive secreted exosomes.
Because exosome formation in MVBs can be
stimulated by calcium ionophores [Savina et al.,
2003], we next investigated the effect of ion-
omycin treatment on the distribution of ErbB1
within intracellular vesicles. To exclude any
toxic effects, we first tested the effect of
ionomycin on cell viability using annexin-V
staining as an early marker of apopotosis. As
shown in Figure 3A, treatment of HaCaT cells
with ionomycin at 1 mM for up to 60 min did not
Fig. 2. Intracellular vesicles containing ErbB1 are released from
the cell as exosomes. A: Cell homogenates were layered on a step
sucrose gradient to separate intracellular vesicles and plasma
membranes. Gradient fractions were analyzed by Western blot
using an antiErbB1 C-terminus antibody. In addition, antibodies
to marker proteins were used in order to confirm the separation of
organelles. EEA1, early endosome antigen 1; BIP/GRP78, bind-
ing protein/glucose-regulated protein 78 (endoplasmic reticulum
marker); LAMP-1, lysosomeassociated membrane protein-1;
TGN, trans Golgi network; ER, endoplasmic reticulum. Plasma
membrane fractions were identified by cell surface biotinylat-
ion followed by homogenization and gradient fractionation.
Biotinylated proteins were detected with Streptavidin-HRP. Note
that ADAM10 has previously been shown to predominantly
localize to the Golgi, TGN and intracellular vesicles by cell
fractionation and immunohistochemistry [Gutwein et al., 2003].
B: Fractions 3–6 from the cell homogenate gradient in A were
pooled and ErbB1 protein fragments analyzed by Western
blotting with the anti-ErbB1 C-terminus antibody. In order to
visualize less represented smaller fragments, the blot was over-
exposed (right panel). Fraction 11 of the gradient, representing
the plasma membrane (PM) and ER components (left panel) was
also analyzed alongside the vesicle fractions.
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induce significant Annexin-V staining. The
stimulation of HaCaT cells for 10 min with
ionomycin led to a decrease of ErbB1 at the cell
surface, whereas ErbB1 levels within the
vesicle/Golgi/TGN fractions increased (Fig. 3B).
This redistribution of ErbB1 into the vesicle/
Golgi/TGN fractions was particularly evident
with the 120 kDa ErbB1 form. Following 30 to
60 min of treatment, ErbB1 levels at the cell
surface and in the vesicle/Golgi/TGN fractions
decreased. Concurrently, levels of ErbB1-con-
taining exosomes secreted into CM increased
over 10, 30, and 60 min of ionomycin treatment
(Fig. 3C).
The effects of ionomycin on ErbB1 trafficking
to exosomes were visualized by immunoflores-
cence analysis using an antibody to the extrac-
ellular ectodomain of ErbB1. In untreated
HaCaT cells, ErbB1 was localized within the
cell and at the cell surface between cell–cell
contacts (Fig. 3D). Treatment with ionomycin
for 20 min resulted in the formation of multiple
punctate vesicle structures which were ErbB1-
positive. Taken together, these results indicate
that ionomycin redirects the ErbB1 receptor
from the plasma membrane and possibly from
the secretory pathway into an intracellular
vesicle pool within MVBs whereupon these
vesicles are released from the cell as exosomes.
Ligand Engagement Leads to Release
of ErbB1 in Exosomes
It is well recognized that ligand stimulation
causes the internalization, endosomal sorting
and accumulation of ErbB1 into MVBs [Futter
et al., 1993, 1996; de Gassart et al., 2004; White
et al., 2006]. We next investigated whether
ligand binding could induce the release of
ErbB1-containing exosomes. EGF treatment
alone or in combination with ionomycin resulted
in higher levels of phosphorylated ErbB1
being secreted in exosomes (Fig. 4A). Based on
the expression of the exosomal marker moesin,
the overall level of exosome release was not
dramatically increased by EGF treatment sug-
gesting that ErbB1 and its phosphorylated form
were being selectively recruited into released
exosomes.
To determine whether the kinase activity
of ErbB1 was necessary for its secretion in
exosomes, we pre-incubated HaCaT cells with
the ErbB1 kinase inhibitor AG1478 prior to
stimulation. EGF-induced release of ErbB1
Fig. 3. Ionomycin leads to ErbB1 trafficking to MVB compart-
ments. A: HaCaT were treated with 1 mM ionomycin for the
indicated length of time and cells were analyzed for apoptosis
using Annexin-V and PI staining and FACS analysis. Treatment
with staurosporine (1 mM) for 16 h served as positive control.
B,C: HaCaT cells were treated with ionomycin (1 mM) for 10, 30,
and 60 min and cell homogenates layered on a step sucrose
gradient as described above. Homogenate gradient fractions and
exosomes isolated from CM were analyzed by Western blot using
the anti-ErbB1 C-terminus antibody. D: HaCaT cells were grown
on glass cover slips and treated with or without ionomycin (1 mM)
for 20 min. Cells were fixed and permeabilized in 3% para-
formaldehyde/Triton X100 and stained with a mouse anti-ErbB1
ectodomain antibody followed by a Cy3-conjugated anti-
mouse IgG secondary antibody. Confocal images were taken in
the DKFZ microscopy division. [Color figure can be viewed in
the online issue, which is available at www.interscience.
wiley.com.]
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containing vesicles was blocked by AG1478
(Fig. 4B), whereas ionomycin-induced secretion
of ErbB1-containing exosomes was not affected
by AG1478 (Fig. 4C). However, depletion of
extracellular calcium with the chelator EGTA
blocked ionomycin-induced exosome release
confirming a role for cellular calcium flux in
this process. These observations are not only
in agreement with previous findings on the
accumulation of ErbB1 in MVBs upon ligand
stimulation [White et al., 2006], but suggest
that physiological stimuli such as ligand-
dependent ErbB1 activation is also involved in
exosome release from cells.
Soluble Isoforms of ErbB1 Are Generated by
Metalloprotease-Mediated Ectodomain Shedding
We have previously shown that ectodomain
shedding of the transmembrane proteins CD44
and L1 can occur at the plasma membrane and
in intracellular vesicles and secreted exosomes
[Gutwein et al., 2005; Stoeck et al., 2006]. The
possibility for such processing of ErbB1 in
HaCaT cells was suggested by the detection of
Fig. 4. EGF activates release of ErbB1 in exosomes. A: HaCaT
cells were treated in the presence or absence of EGF (20 ng/ml)
and ionomycin-calcium salt (1 mM) for 2 h. Exosomes were
isolated from conditioned media by ultracentrifugation and
then analyzed by Western blot using antibodies against the ErbB1
C-terminus, phospho-ErbB1 C-terminus and the exosomal
marker protein moesin. B: HaCaT cells were pre-treated with
or without AG1478 (0.25mM) for 30 min prior to stimulation with
EGF (20 ng/ml). Exosomes were analyzed by Western blot for
ErbB1 as in (A). C: HaCaT cells were pre-incubated for 30 min in
AG1478 (0.25 mM) or EGTA (10 mM) and then treated with
ionomycin (1 mM). Exosomes were then analyzed by Western
blot for ErbB1 as in A.
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smaller immunoreactive C-terminal ErbB1
fragments in secreted exosomes (Figs. 1 and 2).
Further analysis of the total exosome lysate
with an antibody against the C-terminus of
ErbB1 identified the full-length 185 kDa recep-
tor and a ladder of smaller fragments (Fig. 5A).
An anti-ErbB1 ectodomain antibody also detect-
ed the full-length receptor and an additional
150 kDa isoform. This 150 kDa isoform and a
less represented 100 kDa form were also found
to be released into CM and lacked the ErbB1
C-terminus as confirmed by their inability to
be detected by the anti-C-terminus antibody.
These soluble ErbB1 isoforms in CM are
consistent with proteolytically shed ErbB1
ectodomains. The association of the soluble
150 and 100 kDa isoforms with exosomes could
possibly occur via homodimerization with
another full-length transmembrane ErbB1 mol-
ecule on the exosome surface. Several smaller
exosomal ErbB1 bands recognized by the anti-
C-terminus antibodies (65 and phosphorylated
55 kDa) were not detected by the anti-ectodo-
main antibody. This suggests that they could be
C-terminal remnant forms generated following
proteolytic ectodomain shedding.
Levels of the soluble 150 kDa ErbB1 isoform
in CM could be increased following ionomycin
treatment (Fig. 5B). Ionomycin and other
calcium ionophores are strong activators of
Fig. 5. Characterization of ErbB1 isoforms in exosomes and
soluble forms generated by metalloprotease cleavage. A:
Exosomes from HaCaT cell CM were pelleted by ultracentrifu-
gation as described above. Following this, soluble non-mem-
brane associated ErbB1 ectodomains in the supernatant were
immunoprecipitated using a mouse anti-ErbB1 ectodomain
antibody. Exosome and IP samples were analyzed by SDS–
PAGE and Western blotting for the ErbB1 C-terminus, phospho-
ErbB1 C-terminus and N-terminal ErbB1 ectodomain. B: HaCaT
cells were treated for 2 h with; serum-free media with DMSO
(vehicle), ionomycin (1 mM) or PMA (50 ng/ml; left panel),
DMSO or the metalloprotease activator APMA (middle panel), or
ionomycin in the presence of DMSO or the metalloprotease
inhibitor GM6001 (right panel). Exosomes were removed from
the CM by ultracentrifugation and IP performed as described in A.
Samples were then analyzed for soluble ErbB1 levels by Western
blot analysis with a goat anti-ErbB1 ectodomain antibody.
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ADAM10-dependent ectodomain shedding at
the cell surface as well as in intracellular
vesicles and exosomes [Sanderson et al., 2005;
Stoeck et al., 2006]. PMA is a well-characterized
activator of ADAM17-mediated shedding events
which occur at the plasma membrane [Nagano
et al., 2004; Stoeck et al., 2006]. Interestingly,
PMA did not activate ErbB1 release into
CM suggesting that ErbB1 is not subject to
ADAM17mediated cleavage.
The role of a metalloprotease in ErbB1
shedding was confirmed by the stimulatory
effect of the metalloprotease activator APMA
(Fig. 5B). In addition, pre-incubation of
HaCaT cells with the metalloprotease inhibitor
GM6001 reduced levels of soluble 150 kDa
ErbB1 in CM following ionomycin treatment.
Interestingly, in the case of constitutive shed-
ding over 24 h of culture in serum-free media,
metalloprotease inhibitors and inhibitors of
other protease classes (serine, cysteine and
aspartic proteases and aminopeptidases) were
ineffective in blocking ErbB1 shedding (data not
shown). This could reflect that constitutive
proteolytic shedding of the ErbB1 ectodomain
occurs predominantly in an intracellular com-
partment which is not efficiently accessible to
such chemical inhibitors.
Shed ErbB1 Binds the Ligand Betacellulin
A soluble form of the ErbB3 ectodomain,
generated by alternate mRNA splicing, binds
the EGF-like factor Neuregulin-1 (NRG1) with
similar affinity to the transmembrane form of
ErbB3 [Lee et al., 2001]. We therefore inves-
tigated whether shed ErbB1 could bind exoge-
nous ligand betacellulin (BTC) [Dunbar et al.,
1999]. BTC was incubated with concentrated
HaCaT cell CM overnight at 48C. For isolation of
complexes between shed ErbB1 and BTC,
immunoprecipitation was performed using an
anti-ErbB1 ectodomain antibody. Immunopre-
cipitates were then analyzed by Western blot
using anti-BTC and antiErbB1 ectodomain
antibodies. BTC was immunoprecipitated with
shed ErbB1 indicating an interaction between
these proteins (Fig. 6). This suggests that
soluble forms of ErbB1 could modulate the
function of soluble EGF-like factors.
DISCUSSION
ErbB1 is a member of the ErbB receptor
family which plays an important role in the
normal development and homeostasis of multi-
ple tissues and also in tumorigenesis [Olayioye
et al., 2000; Yarden and Sliwkowski, 2001].
In addition to acting as cell surface receptors,
ErbBs and other transmembrane proteins can
undergo a variety of post-translational modifi-
cation events to generate novel proteins with
differing functions. In the case of ErbB2 and
ErbB4, proteolytic processing by metallopro-
teases sheds soluble ectodomain forms of each
molecule [Rio et al., 2000; Molina et al., 2001;
Liu et al., 2006a,b]. Whilst sequential process-
ing of ErbB4 generates a C-terminal fragment
(CTF) which migrates to the nucleus and affects
transcription events [Ni et al., 2001]. Full-
length ErbB receptor proteins can be trafficked
to the nucleus in certain cell types [Lo and
Fig. 6. ErbB1 ectodomains bind the ligand betacellulin (BTC). Concentrated HaCaT CM free of exosomes
was incubated with recombinantBTC and then the ErbB1 ectodomains immunoprecipitated using the mouse
anti-ErbB1 ectodomain antibody and protein-A sepharose. As controls, BTC or CM alone were used.
Immunoprecipitates were analyzed by Western blot using rabbit anti-BTC and goat anti-ErbB1 ectodomain
antibodies.
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Hung, 2006], whereas other full-length trans-
membrane proteins can be secreted in exosomes
[Taverna et al., 2003; Hakulinen et al., 2004;
Hawari et al., 2004; Stoeck et al., 2006]. In this
study, we demonstrate that the full-length and
smaller processed forms of ErbB1 are secreted
in exosomes and that the soluble immunoreac-
tive ErbB1 fragments are generated by proteo-
lytic processing.
Secretion of full-length and proteolysed
ErbB1 isoforms in exosomes was upregulated
by treatment with EGF and the calcium
ionophore ionomycin. The generation of exo-
somes in response to calcium flux is a well-
characterized process [Savina et al., 2003],
whereas upon ligand binding, ErbB1/ligand
complexes are trafficked from the cell surface
into MVBs and both proteins are subsequently
degraded or the receptor is re-routed to the cell
surface [Futter et al., 1993, 1996; de Gassart
et al., 2004; White et al., 2006]. Our findings
indicate that ligand (EGF) binding also results
in a portion of ErbB1 being secreted from
MVBs in exosomes. Consistent with earlier
findings that the kinase domain of ErbB1 is
required for intracellular trafficking to MVBs
[Felder et al., 1990], we demonstrated that the
ErbB1 kinase inhibitor AG1478 blocked secre-
tion of ErbB1-containing exosomes following
EGF treatment. Trafficking of ErbB1 to exo-
somes following EGF or ionomycin treatment
likely represents a common pathway. Forma-
tion of exosomes following calcium flux and also
the recruitment of ErbB1/ligand complexes to
MVBs are dependent on the calcium-binding
protein annexin-1 [Radke et al., 2004; Gerke
et al., 2005]. Calcium flux leads to the redis-
tribution of annexin-1 to the plasma membrane
and the inward formation of intracellular endo-
somal vesicles [Rescher and Gerke, 2004]. In
this report, and our earlier work in ovarian
carcinoma cell lines [Stoeck et al., 2006], we
demonstrated that ionophore-induced exosom-
es contain annexin-1. Following ligand binding,
ErbB1 binds and phosphorylates annexin-1 and
this process drives trafficking of the receptor/
ligand complex to MVBs [Futter et al., 1993;
Radke et al., 2004]. In addition, other calcium
binding proteins including calmodulin have
been demonstrated to interact with the ErbB1
receptor and modulate its endosomal/lysosomal
trafficking and recycling to the plasma membr-
ane [Li and Villalobo, 2002; Tebar et al., 2002].
Further work is warranted to elucidate the role
of annexin-1 and other calcium-regulated pro-
teins in ErbB1 trafficking to exosomes.
In addition to the trafficking of ErbB1 into
exosomes, calcium flux and the metalloprotease
activator APMA stimulated proteolytic shed-
ding of the ErbB1 ectodomain. We have pre-
viously found that these two stimuli are strong
activators of the metalloprotease ADAM10
[Sanderson et al., 2005; Stoeck et al., 2006].
Ectodomain shedding of ErbB1 generated a
major 150 kDa soluble form and smaller
membrane-associated C-terminal fragments
(CTFs) lacking the ectodomain. These remnant
forms were only present in the Golgi/TGN/
vesicle fractions of cell homogenate gradients
suggesting that, like the L1 adhesion molecule
[Stoeck et al., 2006], shedding of ErbB1 occurs
predominantly inside the cell. Consistent with
this, ADAM10 was present predominantly in
the same intracellular fractions as full-length
and cleaved ErbB1 isoforms. Numerous studies
have identified that ligands for ErbB receptors
(EGF-like factors) such as HB-EGF and TGFa
undergo ADAM-mediated shedding in response
to pharmacological agents including phorbol
esters and ionophores [Pandiella and Mas-
sague, 1991a,b] as well as physiological activa-
tors such as G-protein coupled receptor (GPCR)
agonists [Prenzel et al., 1999]. Shed EGF-like
factors then ‘transactivate’ the ErbB1 receptor
and this process appears to be particularly
important for driving the growth of certain
cancer cell lines [Fischer et al., 2003]. We have
now identified that ErbB1 is also proteolysed to
a soluble form following cell stimulation and
that shed ErbB1 retained the ability to bind the
EGF-like factor BTC. These findings raise the
possibility that soluble ErbB1 forms could
regulate the activity of shed EGF-like factors
and cell growth and this may highlight an as yet
uncharacterized component of the transactiva-
tion process.
In summary, the work presented here identi-
fies novel protein forms of ErbB1 which are
generated by proteolytic processing and secre-
tion in exosomes. It is possible that each ErbB1
isoform could play a novel and as yet unrecog-
nized function in the normal and tumorigenic
activity of ErbB1 and such investigations are
warranted in the future.
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